News & press releases

News & press releasesmonimono2017-12-05T08:33:16+00:00

February 26, 2019

Exalenz Bioscience Receives Approval for Commercial Marketing in China for its BreathID® Hp Lab System

November 15, 2018

Exalenz Announces Third Quarter 2018 Financial Results

November 5, 2018

Exalenz to Present Positive Clinical Data for the Breath ID® 13C-Methacetin Breath Test System at the Liver Meeting® 2018

August 31, 2018

Exalenz Announces Second Quarter 2018 Financial Results

Exalenz Bioscience’s Non-Invasive BreathID® Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH

Exalenz Announces Confidential Submission of Draft Registration Statement for Initial Public Offering

Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer

Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients

Exalenz Announces Fourth Quarter and Full Year 2017 Financial Results

Exalenz Bioscience to Participate in Upcoming Investor Conferences

January 23, 2018

Exalenz Bioscience announces positive clinical trial results for the diagnosis of clinically significant portal hypertension in NASH patients

Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017

Exalenz Bioscience Receives FDA Marketing Clearance for its Laboratory System in the United States